For further drug development, compounds from natural sources with dual aromatase and sulfatase inhibitory activities might also be of interest, such as a traditional Chinese herbal formula (Shu-Gan-Liang-Xue decoction) that is used for treatment of patients with breast cancer in traditional Chinese medicine (Zhou et al., 2014). Here, CYP19A1 is linked to breast carcinoma.